Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

conatumumab

A fully human monoclonal agonist antibody directed against the extracellular domain of human TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) receptor 2 (TR-2) with potential antineoplastic activity. Conatumumab mimics the activity of native TRAIL, binding to and activating TR-2, thereby activating caspase cascades and inducing tumor cell apoptosis. TR-2 is expressed by a variety of solid tumors and cancers of hematopoietic origin.
Synonym:anti-TRAIL receptor 2 monoclonal antibody AMG 655
immunoglobulin G1, anti-(human tumor necrosis factor receptor superfamily member 10b (death receptor 5, trail-R2, CD262 antigen))
monoclonal XG1-048 (Arg(Sup 219),Glu(Sup 361),Met(Sup 363))gamma-1 heavy chain (225-215')-disulphide with kappa light chain (231-231'':234-234'')-bisdisulphide dimer
Code name:AMG 655
Chemical structure:immunoglobulin G1, anti-(human cytokine receptor DR5 (death receptor 5)) (human monoclonal XG1-048 v w heavy chain), disulfide with human monoclonal XG1-048 v w light chain, dimer
immunoglobulin G1, anti-(human tumor necrosis factor receptor superfamily member 10B (death receptor 5, TRAIL-R2, CD262 antigen)); human monoclonal XG1-048 [Arg219,Glu361,Met363]γ1 heavy chain (225-215')-disulfide with κ light chain (231- 231'':234-234'')-bisdisulfide dimer
Search NCI's Drug Dictionary